Search

Displaying results 5311 - 5320 of 7540 in total
  1. Drug

    NGX267

    go.drugbank.com/drugs/DB05152
    Investigational

    It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

  2. Drug

    TC-5231

    go.drugbank.com/drugs/DB05333
    Experimental

    TC-5231 is mecamylamine hydrochloride, the active ingredient in FDA-approved product, Inversine, but in a lower dose than Inversine.

  3. Drug

    RESP301

    go.drugbank.com/drugs/DB16497
    Investigational

    Additionally, RESP301 was investigated in a withdrawn trial (NCT04842331) for preventing viral exposure and transmission of COVID-19 and in a not yet recruiting trial (NCT04386070) for preventing pulmonary

  4. Drug

    Zosuquidar

    go.drugbank.com/drugs/DB06191
    Investigational

    It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.

  5. Drug

    Atrazine

    go.drugbank.com/drugs/DB07392
    Experimental

    Inhalation hazard is low and there are no apparent skin manifestations or other toxicity in humans.

  6. Drug

    Cloxazolam

    go.drugbank.com/drugs/DB01553
    Experimental

    Cloxazolam is a benzodiazepine with anxiolytic, sedative/hypnotic, muscle relaxant, and antiepileptic effects. It is marketed in the Argentina, Australia, Portugal, Belgium, Switzerland, Luxembourg, Germany, Taiwan and Japan -- mainly fo...

  7. Drug

    AG0301-COVID19

    go.drugbank.com/drugs/DB15856
    Investigational

    AG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University. … On September 8, 2020 AnGes announced collaboration with Brickell Biotech, Inc. following completion of Phase 1/2 clinical studies (NCT04463472).

  8. Drug

    Dichlorvos

    go.drugbank.com/drugs/DB11397
    ExperimentalVet approved

    The compound has been available on the market since 1961 and its use is a controversial topic due to environmental and health concerns. … Dichlorvos is found in urban waterways and its toxicity may impact humans, leading to poisoning, neurotoxicity, and cancer.

  9. Drug

    Caroxazone

    go.drugbank.com/drugs/DB09254
    ApprovedWithdrawn

    Caroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes. However, it presents a five-fold preference for the MAO-B subtype.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    PF-07799933

    go.drugbank.com/drugs/DB17489
    Investigational

    PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.